The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
The NF1 tumor suppressor critically regulates TSC2 and mTOR
Open accessAbstract
Loss-of-function mutations in the NF1 tumor suppressor gene underlie the familial cancer syndrome neurofibromatosis type I (NF1). The NF1 -encoded protein, neurofibromin, functions as a Ras-GTPase activating protein (RasGAP). Accordingly, deregulation of Ras is thought to contribute to NF1 development. However, the critical effector pathways involved in disease pathogenesis are still unknown. We show here that the mTOR pathway is tightly regulated by neurofibromin. mTOR is constitutively activated in both NF1 -deficient primary cells and human tumors in the absence of growth factors. This aberrant activation depends on Ras and PI3 kinase, and is mediated by the phosphorylation and inactivation of the TSC2 -encoded protein tuberin by AKT. Importantly, tumor cell lines derived from NF1 patients, and a genetically engineered cell system that requires Nf1 -deficiency for transformation, are highly sensitive to the mTOR inhibitor rapamycin. Furthermore, while we show that the activation of endogenous Ras leads to constitutive mTOR signaling in this disease state, we also demonstrate that in normal cells Ras is differentially required for mTOR signaling in response to various growth factors. Thus, these findings identify the NF1 tumor suppressor as an indispensable regulator of TSC2 and mTOR. Furthermore, our results also demonstrate that Ras plays a critical role in the activation of mTOR in both normal and tumorigenic settings. Finally, these data suggest that rapamycin, or its derivatives, may represent a viable therapy for NF1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
Marshall, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90401-8 · Cited by 3,906
Robbins and Cotran Pathologic Basis of Disease
Hoda, S. A., & Hoda, R. S. (2020) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqaa163 · Cited by 3,365
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083
Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling
Inoki, K., Li, Y., Xu, T., & Guan, K.-L. (2003) · Genes & Development · doi:10.1101/gad.1110003 · Cited by 1,911
Addiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728
Manning, B. D., Tee, A. R., Logsdon, M. N., Blenis, J., & Cantley, L. C. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00568-3 · Cited by 1,555
Targeting the PI3K-Akt pathway in human cancer
Luo, J., Manning, B. D., & Cantley, L. C. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00248-4 · Cited by 1,290
Fingar, D. C., & Blenis, J. (2004) · Oncogene · doi:10.1038/sj.onc.1207542 · Cited by 1,247
Tee, A. R., Manning, B. D., Roux, P. P., Cantley, L. C., & Blenis, J. (2003) · Current Biology · doi:10.1016/s0960-9822(03)00506-2 · Cited by 1,080
The LKB1 tumor suppressor negatively regulates mTOR signaling
Shaw, R. J., Bardeesy, N., Manning, B. D., Lopez, L., Kosmatka, M., DePinho, R. A., & Cantley, L. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.007 · Cited by 1,077
Insulin Activation of Rheb, a Mediator of mTOR/S6K/4E-BP Signaling, Is Inhibited by TSC1 and 2
Garami, A., Zwartkruis, F. J. T., Nobukuni, T., Joaquin, M., Roccio, M., Stocker, H., Kozma, S. C., Hafen, E., Bos, J. L., & Thomas, G. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00220-x · Cited by 1,043
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
Neshat, M. S., Mellinghoff, I. K., Tran, C., Stiles, B., Thomas, G., Petersen, R., Frost, P., Gibbons, J. J., Wu, H., & Sawyers, C. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171076798 · Cited by 969
Akt regulates growth by directly phosphorylating Tsc2
Potter, C. J., Pedraza, L. G., & Xu, T. (2002) · Nature Cell Biology · doi:10.1038/ncb840 · Cited by 959
Modelling the molecular circuitry of cancer
Hahn, W. C., & Weinberg, R. A. (2002) · Nature Reviews Cancer · doi:10.1038/nrc795 · Cited by 944
Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins
Zhang, Y., Gao, X., Saucedo, L. J., Ru, B., Edgar, B. A., & Pan, D. (2003) · Nature Cell Biology · doi:10.1038/ncb999 · Cited by 923
Neurofibromatosis, Phenotype, Natural History, and Pathogenesis
Riccardi, V. M., & Smirniotopoulos, J. (1992) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199211000-00009 · Cited by 893
Roux, P. P., Ballif, B. A., Anjum, R., Gygi, S. P., & Blenis, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405659101 · Cited by 750
Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients
Basu, T. N., Gutmann, D. H., Fletcher, J. A., Glover, T. W., Collins, F. S., & Downward, J. (1992) · Nature · doi:10.1038/356713a0 · Cited by 668
Kwiatkowski, D. J. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.5.525 · Cited by 667
Neurofibromas in NF1: Schwann Cell Origin and Role of Tumor Environment
Zhu, Y., Ghosh, P., Charnay, P., Burns, D. K., & Parada, L. F. (2002) · Science · doi:10.1126/science.1068452 · Cited by 633
The target of rapamycin (TOR) proteins
Raught, B., Gingras, A.-C., & Sonenberg, N. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.121145898 · Cited by 605
NF1 Tumor Suppressor Gene Function
Cichowski, K., & Jacks, T. (2001) · Cell · doi:10.1016/s0092-8674(01)00245-8 · Cited by 601
Self-citationBollag, G., Clapp, D. W., Shih, S., Adler, F., Zhang, Y. Y., Thompson, P., Lange, B. J., Freedman, M. H., McCormick, F., Jacks, T., et al. (1996) · Nature Genetics · doi:10.1038/ng0296-144 · Cited by 589
DeClue, J. E., Papageorge, A. G., Fletcher, J. A., Diehl, S. R., Ratner, N., Vass, W. C., & Lowy, D. R. (1992) · Cell · doi:10.1016/0092-8674(92)90407-4 · Cited by 580
An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/−mice
Podsypanina, K., Lee, R. T., Politis, C., Hennessy, I., Crane, A., Puc, J., Neshat, M., Wang, H., Yang, L., Gibbons, J., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171060098 · Cited by 569
Corradetti, M. N., Inoki, K., Bardeesy, N., DePinho, R. A., & Guan, K.-L. (2004) · Genes & Development · doi:10.1101/gad.1199104 · Cited by 560
Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR
Zhang, H., Cicchetti, G., Onda, H., Koon, H. B., Asrican, K., Bajraszewski, N., Vazquez, F., Carpenter, C. L., & Kwiatkowski, D. J. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17222 · Cited by 538
Mouse Models of Tumor Development in Neurofibromatosis Type 1
Cichowski, K., Shih, T. S., Schmitt, E., Santiago, S., Reilly, K., McLaughlin, M. E., Bronson, R. T., & Jacks, T. (1999) · Science · doi:10.1126/science.286.5447.2172 · Cited by 467
Self-citationAntileukemic activity of rapamycin in acute myeloid leukemia
Récher, C., Beyne-Rauzy, O., Demur, C., Chicanne, G., Dos Santos, C., Mas, V. M.-D., Benzaquen, D., Laurent, G., Huguet, F., & Payrastre, B. (2005) · Blood · doi:10.1182/blood-2004-06-2494 · Cited by 296
Serra, E. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.20.3055 · Cited by 254
Confirmation of a Double-Hit Model for the NF1Gene in Benign Neurofibromas
Serra, E., Puig, S., Otero, D., Gaona, A., Kruyer, H., Ars, E., Estivill, X., & Lázaro, C. (1997) · The American Journal of Human Genetics · doi:10.1086/515504 · Cited by 242
Harris, T. E., & Lawrence, J. C. (2003) · Science's STKE · doi:10.1126/stke.2122003re15 · Cited by 234
Activation of p70/p85 S6 kinase by a pathway independent of p21fi ras
Ming, X.-F., Burgering, B. M. T., Wennstrom, S., Claesson-Welsh, L., Heldin, C.-H., Bos, J. L., Kozma, S. C., & Thomas, G. (1994) · Nature · doi:10.1038/371426a0 · Cited by 206
Will mTOR inhibitors make it as cancer drugs?
Sawyers, C. L. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00275-7 · Cited by 190
Integration of Growth Factor and Nutrient Signaling
Shamji, A. F., Nghiem, P., & Schreiber, S. L. (2003) · Molecular Cell · doi:10.1016/j.molcel.2003.08.016 · Cited by 186
Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressorPreprint
Cichowski, K. M., Santiago, S., Jardim, M. J., Johnson, B. W., & Jacks, T. (2003) · Genes & Development · doi:10.1101/gad.1054703 · Cited by 163
Self-citationKluwe, L., Friedrich, R. E., & Mautner, V. (1999) · Genes Chromosomes and Cancer · Cited by 149
Kim, H. A., Rosenbaum, T., Ma, M., Ratner, N., & DeClue, J. E. (1995) · PubMed · Cited by 134
Neurofibromin GTPase-activating Protein-related Domains Restore Normal Growth in Nf1−/− Cells
Hiatt, K. K., Ingram, D. A., Zhang, Y., Bollag, G. E., & Clapp, D. W. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009202200 · Cited by 126
Bader, J. L. (1986) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1986.tb48062.x · Cited by 110
Frahm, S., Mautner, V., Brems, H., Legius, E., Dêbiec‐Rychter, M., Friedrich, R. E., Knöfel, W. T., Peiper, M., & Kluwe, L. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.01.006 · Cited by 97
Self-citationDonovan, S., See, W. L., Bonifas, J. M., Stokoe, D., & Shannon, K. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00214-3 · Cited by 62
Long-term culture and characterization of human neurofibroma-derived Schwann cells
Rosenbaum, T., Rosenbaum, C., Winner, U., M�ller, H. W., Lenard, H. G., & Hanemann, C. O. (2000) · Journal of Neuroscience Research · doi:10.1002/1097-4547(20000901)61:5<524::aid-jnr7>3.0.co;2-z · Cited by 57
Cited by
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019
A Lentiviral RNAi Library for Human and Mouse Genes Applied to an Arrayed Viral High-Content Screen
Moffat, J., Grueneberg, D. A., Yang, X., Kim, S. Y., Kloepfer, A. M., Hinkle, G., Piqani, B., Eisenhaure, T. M., Luo, B., Grenier, J. K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.01.040 · Cited by 1,798
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789
Metadata
- Authors
- Johannessen, C. M., Reczek, E. E., James, M. F., Brems, H., Legius, E., & Cichowski, K.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2005-06-03
- Volume
- 102
- Issue
- 24
- Pages
- 8573-8578
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2073355522
- Cited by
- 601
- References
- 44
- FWCI
- 11.52
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.